Three Houston innovators discussed the strides the city is making in terms of equitable funding opportunities. Photos courtesy

Houston has consistently been recognized as one of the most diverse cities in the country — but is that translating into equitable funding opportunities for diverse founders? A panel at SXSW this year discussed whether or not Houston's playing field is level for people of color within the innovation ecosystem.

"People do business with who they know — and who they like," says Felix Chevalier, co-founder of Urban Capital Network, when the panel was asked where the disconnect is with funding diverse founders. "I think it boils down to a lack of exposure and a lack of relationships."

Chevalier was joined by Jesse Martinez of Resolved Ventures and VamosVentures and Denise Hamilton of WatchHerWork, who moderated the discussion, which was hosted in the Greater Houston Partnership's Houston House on Sunday, March 13, at SXSW in Austin.

"We have to look at the pipeline — what the existing ecosystem looks like," says Martinez, who leads the LatinX Alliance, an organization that's relocating its operations to Houston. "We have new funds, new diverse GPs, and we have more investors — and we're building talent. ... We are making great strides, but we still need more of us to be funding our diverse founders."

The key to the equation, the panelists agreed, is education and programming — both for potential investors, like UCN does with its hands-on support for its diverse investor base, and for founders of color who might be more hesitant to plunge by starting a company.

"The way you start to dissolve that fear for folks, for example, who may be in a corporate space but may want to spread their entrepreneur wings, is to just get involved with the ecosystem," Chevalier says. "What ends up happening is you bump into someone you know or someone who is from the same talent you are originally — all you have to do is immerse yourself in the environment."

"The opportunities are out there, but it is incumbent upon in those who want it to put themselves in a position to meet people who are in the environments that are going to help facilitate whatever your objectives are," he continues.

Hamilton explained her experience raising money as a Black woman — investors didn't want to bet on her. It's a chicken and an egg situation, she says, and support for diverse founders in terms of programming and investors focused specifically on underserved communities are going to help break the cycle. It's not about charity, but equitable opportunities.

"I don't want any charity – I don't want an overabundance of kindness. Scaffold me like you scaffolded Mark Zuckerberg," Hamilton says, giving Facebook as an example of a company that was supported in a way she never had. "If you are going to be in a nascent ecosystem, you need to have structures that explain why your pitch deck has to be efficient, why you need a team. We've got to not focus just on the money piece, but on this whole psychosocial aspect."

With Hamilton's call to Houston's development as an equitable tech ecosystem, the conversation turned to discuss whether or not Houston is ready to provide this support to startups and rise to being the global innovation hub the city wants to be.

"We've got to find our tribe. We have all the pieces," Martinez says. "It's going to take time, and we have to be very intentional. ... It's really about thinking of Houston as a startup itself. How do we act as a team, and bring in partners and investors to make it a thriving ecosystem over time."

It takes commitment, Hamilton says, and that's happening in the Bayou City.

"Everything is not figured out right now — but there's a commitment to figuring it out," she says. "It's not going to be Silicon Valley overnight — it will never be Silicon Valley. Because this is Houston."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston researchers report promising first in-human trial for implantable cancer therapy

cancer breakthrough

When it comes to cancer remedies, the treatment can be as challenging for the body as its cause. But what if immunotherapy could be localized? That’s precisely what a Houston team may soon make a reality.

Rice University researchers, in partnership with MD Anderson Cancer Center, recently published their findings from the first in-human trial of an implantable cancer-fighting treatment in the journal Clinical Cancer Research. The paper details testing of AVB-001, encapsulated cells engineered to release interleukin-2 (IL-2)—a naturally occurring signaling protein that boosts immunity—in the peritoneal cavities of 14 patients. The goal is to avoid the toxicity usually experienced with less targeted treatments, as well as find a solution to IL-2s’ abbreviated half-lives.

“Traditional IL-2 therapy has shown potent antitumor activity, but its clinical use has been limited by severe side effects and delivery challenges,” Omid Veiseh, director of the Rice Biotech Launch Pad, professor of bioengineering at Rice and a senior author on the study, said in a press release. “This platform allows us to localize and sustain cytokine exposure directly where tumors reside while minimizing systemic toxicity.”

Serous ovarian carcinoma is especially well-suited to the use of AVB-001 because it tends to spread throughout the abdomen. After a minimally invasive laparoscopic procedure, patients implanted with the cells were noted to tolerate the treatment well. Half of the enrolled patients’ cancer was stabilized, with several among them reporting extended signs of benefit. No maximum tolerated dose was reached and there were no life-threatening events tied to the study.

If that sounds like less-than-earth-shaking results, this is only the beginning. The capsules were implanted for about one week because IL-2 activity drops off after that. The researchers now know that further testing should include either higher levels, repeated doses, or a combination thereof, in order to create stronger advances.

The team has already made early headway on this next step. Preclinical studies in nonhuman primates were not only tolerated well, but without added toxicity, the apes had consistent pharmacological effects.

“This is a foundational step,” Veiseh explained. “We now have evidence that the platform is safe, biologically active and potentially scalable. The next phase is optimizing dosing and exploring combination therapies to unlock its full clinical potential.”

The combination would also include a checkpoint inhibitor, which might improve AVB-001’s tumor-fighting power. “What is exciting is that we are not just delivering a drug, we are programming a microenvironment,” added Dr. Amir Jazaeri, professor of gynecologic oncology at MD Anderson, member of the Rice Biotech Launch Pad’s clinical advisory board and a senior author on the study. “This opens the door to combination strategies that could amplify immune responses in ways that have not been feasible before.”

Houston startup raises $6M to scale home-based healthcare platform

fresh funding

As healthcare systems race to expand care beyond hospitals and into the home, investors are placing bigger bets on the infrastructure needed to make that shift possible.

This month, Rosarium Health announced it has raised $6 million in seed funding led by Kalos Ventures, with participation from ResilienceVC, Rock Health Capital, Symphonic Capital, Black Tech Nations Ventures and others.

The investment will help the Houston-based startup continue to build its platform, which features a national network of 800-plus clinicians and 3,000-plus contractors to coordinate home accessibility upgrades and modifications for seniors and people living with disabilities.

For founder and CEO Cameron Carter, the company’s mission grew out of firsthand caregiving experiences.

“From my own personal caregiving experiences, I realized that the benefits exist on paper, but not in reality,” Carter said in a news release. “Families are being left to figure out the paperwork and installations all on their own, which shouldn’t be how this works.”

While Medicare Advantage and Medicaid plans have expanded coverage for home-based services and accessibility modifications, the logistics behind delivering those services often remain fragmented.

Rosarium’s platform coordinates the entire process, from clinical assessments and referrals to contractor management, documentation, reimbursement and installation.

“A clinician can document that a home isn’t safe and a plan can approve a benefit, but there’s no one that’s responsible for making sure the work actually gets done,” Carter says. “We built the missing piece.”

The company was founded in 2021 as Rose Health and was a 2023 participant in the Texas Medical Center’s Accelerator for HealthTech program. It has scaled quickly, building a network of more than 800 clinicians and 3,000 contractors across 34 states.

Rosarium is currently in-network for 1.2 million Medicare and Medicaid lives, with projected coverage expected to reach nearly 4 million by the end of the year, according to the release.

“We’re excited to back Cameron because he and the team at Rosarium are building the infrastructure healthcare needs right now to make the home a safe and comfortable place of care,” Kate Ballinger, investor at Kalos Ventures, added in the release.

As part of the recent investment, Ballinger will join Rosarium’s board of directors.

With eyes on the future, Rosarium plans to grow its partnerships with Medicaid and Medicare Advantage plans, including CalViva and Community Health Plan of Imperial Valley, strengthening its presence in California while expanding access to underserved communities.

Additionally, Carter predicts that home-based healthcare will be part of a broader transformation happening across the industry.

“There’s a growing recognition that health outcomes are shaped by what happens in the home,” he said in the release. “The future of healthcare isn’t just treating people after something goes wrong. It’s creating environments that help prevent those problems in the first place.”